We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
-0.84%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$242K
AUM Growth
-$247M
Cap. Flow
+$20M
Cap. Flow %
8,259.72%
Top 10 Hldgs %
57.4%
Holding
86
New
15
Increased
42
Reduced
10
Closed
17

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$7.21M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$5.91M
3
VCYT icon
Veracyte
VCYT
+$5.84M
4
APLS
Apellis Pharmaceuticals
APLS
+$4.65M
5
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$3.13M

Top Sells

Rank Stock Value
1
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$5.42M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$5.38M
3
IMGN
Immunogen Inc
IMGN
+$4.81M
4
HALO icon
Halozyme
HALO
+$2.85M
5
CYTK icon
Cytokinetics
CYTK
+$2.65M

Sector Composition

Rank Sector Weight
1 Healthcare 85.36%
2 Financials 1.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELOX
51
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$1.09K 0.45%
48,774
+522
+1% +$10.3K
PSTX
52
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1.07K 0.44%
239,696
+4,764
+2% +$21.5K
NXTC icon
53
NextCure
NXTC
$16.8M
$953 0.39%
16,349
+265
+2% +$16.6K
CGEN icon
54
Compugen
CGEN
$222M
$865 0.36%
268,596
+105,994
+65% +$358K
IMUX icon
55
Immunic
IMUX
$190M
$774 0.32%
+6,848
New +$793K
CLYM
56
Climb Bio
CLYM
$681M
$741 0.31%
+88,279
New +$824K
APTX
57
PUT
DELISTED
Aptinyx Inc. Common Stock
APTX
$458 0.19%
+201,600
New +$604K
AMLX icon
58
Amylyx Pharmaceuticals
AMLX
$2.26B
$386 0.16%
+30,000
New +$678K
EVGN icon
59
Evogene
EVGN
$5.7M
$384 0.16%
29,575
+269
+0.9% +$3.63K
MREO
60
Mereo BioPharma
MREO
$54.7M
$264 0.11%
235,515
+2,332
+1% +$3.02K
CLDX icon
61
Celldex Therapeutics
CLDX
$2.99B
$256 0.11%
45,538
+406
+0.9% +$13K
BIIB icon
62
Biogen
BIIB
$30B
$230 0.1%
10,248
+4,504
+78% +$979K
BCRX icon
63
BioCryst Pharmaceuticals
BCRX
$2.28B
$197 0.08%
+102,425
New +$1.64M
BLU
64
DELISTED
BELLUS Health Inc.
BLU
$177 0.07%
1,235,784
+135,784
+12% +$875K
CALA
65
DELISTED
Calithera Biosciences, Inc
CALA
$74 0.03%
11,090
+100
+0.9% +$1.02K
BNTC icon
66
Benitec Biopharma
BNTC
$402M
$57 0.02%
28,993
-5,566
-16% -$231K
RCOR.WS
67
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$33 0.01%
104,828
– –
ALGS icon
68
Aligos Therapeutics
ALGS
$26.2M
$23 0.01%
+426
New +$34.1K
MSACW
69
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$21 0.01%
49,990
– –
AUPH icon
70
Aurinia Pharmaceuticals
AUPH
$1.91B
– –
-100,000
Closed -$2.29M
BBIO icon
71
BridgeBio Pharma
BBIO
$15.7B
– –
-100,000
Closed -$1.67M
CGEN icon
72
CALL
Compugen
CGEN
$222M
– –
-57,000
Closed -$245K
CRIS icon
73
CALL
Curis
CRIS
$9.78M
– –
-500
Closed -$952K
CYTK icon
74
Cytokinetics
CYTK
$10.5B
– –
-58,190
Closed -$2.65M
HALO icon
75
Halozyme
HALO
$9.79B
– –
-71,009
Closed -$2.85M
1 2
3
4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Silverarc Capital Management held 86 positions worth $242K, down 100% from $247M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Silverarc Capital Management deployed $20M of net new capital in Q1 2022, opening 15 new positions and adding to 42 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 105,368 shares worth $5.35K.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 84% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $5.38M trimmed.

  • Silverarc Capital Management's largest Q1 2022 buy was Apellis Pharmaceuticals: 105,368 shares worth $5.35K.
  • Silverarc Capital Management added most to Sierra Oncology, Inc. Common Stock in Q1 2022, an estimated $7.21M increase.
  • Silverarc Capital Management's biggest Q1 2022 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $5.38M.
  • Silverarc Capital Management fully exited Research Alliance Corp. II Class A Common Stock in Q1 2022, selling an estimated $5.42M.
  • Silverarc Capital Management's ten largest holdings make up 57% of its $242K portfolio in Q1 2022.
  • Silverarc Capital Management opened 15 new positions and closed 17 in Q1 2022.
  • Silverarc Capital Management's portfolio value fell 100% quarter-over-quarter to $242K.

Based on Silverarc Capital Management's 13F filing for Q1 2022, filed 13 May 2022.